ArticleProbiotics and antimicrobial proteins2026
Computational Discovery of Novel CYP51 Inhibitors for Antifungal Therapy Against Aspergillus fumigatus.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lanosterol 14-alpha demethylase (CYP51), encoded by the Erg11 gene, is a crucial enzyme in pathogenic fungi. It catalyzes the demethylation of lanosterol to ergosterol, a vital component of fungal cell membranes. Inhibition of CYP51 disrupts ergosterol biosynthesis, compromises membrane integrity, and inhibits fungal growth, making it a key target for antifungal therapy. In this study, we employed a comprehensive computational approach comprising molecular docking, drug-likeness analysis, dynamics simulations, pharmacophoric feature modeling, ADMET profiling, and pharmacokinetic (PK) simulations to identify novel CYP51 inhibitors from a library of 1,200 plant-derived metabolites. Of these, 211 compounds exhibited stronger binding affinities than voriconazole, a widely used antifungal agent. The top 10 metabolites showed strong interactions with key substrate recognition sites (SRS1, SRS2, SRS4, and SRS6) of CYP51. MD simulations of the top three candidates, Boeravinone D, Nimbidin, and 7-acetyl neotrichilenone, revealed stable binding conformations primarily driven by non-polar interactions, as confirmed by MM/GBSA binding free energy calculations. Notably, Nimbidin exhibited the most favorable binding energetics, supported by Gibbs free energy and hydrogen bonding analyses. Principal component analysis (PCA) further indicated distinct and stable dynamic behaviors of the ligand-protein complexes. Pharmacokinetic simulations suggested that Boeravinone D and Nimbidin may maintain prolonged plasma concentrations, indicating strong therapeutic potential. All three candidates showed favorable ADMET profiles, although 7-acetyl neotrichilenone may require optimization to improve solubility. These findings identify Boeravinone D, Nimbidin, and 7-acetyl neotrichilenone as promising CYP51 inhibitors. Further in vitro and in vivo studies are warranted to validate their antifungal efficacy and advance them as potential therapeutic agents.
Indexed as
Identifiers
42640517What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.